Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07141914 · ClinicalTrials.gov registry record
A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 285,327
- Enrollment target
NCT07141914: Completed study, sponsored by Novo Nordisk A/S.
NCT07141914 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 285,327 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07141914 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 285,327 participants
- Enrollment target
Study Summary
This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic Cardiovascular Disease (ASCVD), primary prevention). This is a retrospective cohort study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for participants in the US during January 1, 2016 - December 31, 2024.
Primary Outcome
Measured as Months Occurrence of any of the following individual component events: 1. Myocardial infarction (MI) 2. Stroke 3. Hospitalization for HF 4. Coronary revascularization (including coronary artery bypass grafting and percutaneous coronary intervention) 5. All-cause mortality The event date will be the earliest occurrence of one of the individual components.
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285,327 participants |
| Start Date | 2025-08-29 |
| Est. Completion | 2025-12-19 |
What the finished NCT07141914 record still lists
NCT07141914 is an observational study that tracks outcomes without assigning an intervention. Its 285,327 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT07141914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07141914 about?
NCT07141914 is a clinical study titled "A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World". This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic Cardiovascular Disease (ASCVD), primary prevention). This is a retrospecti...
What is the current status of trial NCT07141914?
This trial is currently completed. The enrollment target is 285,327 participants. The study started on 2025-08-29. Estimated completion is 2025-12-19.
What interventions are being tested in trial NCT07141914?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT07141914?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
- NCT07314697 · 300,000 participants · NA
Arrival Time Implementation
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI